

Presentation and Chair's address to the 2024 Annual General Meeting

20 November 2024

4DMedical Limited (ASX:4DX, "4DMedical" or the "Company") attaches the following materials to be presented at the Annual General Meeting of Shareholders to be held today at 10.00am AEDT:

1. Script of the prepared address to be given by the Chair; and
2. Presentation slides to accompany the meeting.

–ENDS–

Authorised by the 4DMedical Company Secretary.

Contacts

Corporate

Chief Financial Officer
Simon Glover
sglover@4dmedical.com

Administration

Company Secretary
Naomi Lawrie
companysecretary@4dmedical.com

Media Enquiries

4dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalised care for patients.

To learn more, please visit www.4dmedical.com and www.imbio.com



4DMedical Limited

Annual General Meeting

Chair's Address

10.00AM, Wednesday, 20 November 2024

Good morning Shareholders and fellow Directors,

Welcome to the 4DMedical 2024 Annual General Meeting.

Today we are gathered on the traditional lands of the Wurundjeri peoples of the Kulin nation, and I pay my respects to their elders past, present and emerging.

As we have a quorum, I formally declare the meeting open.

FY2024 Overview

Firstly my sincere thanks to our investors, both institutional and retail, who have supported the Company throughout the year and especially the acquisition of Imbio.

The past year has seen the Company achieve commercial revenue, widen our customer base and build focused pathways to growth in the U.S. market. The signing of our reseller agreement with Philips significantly expands our U.S. reach and commercial opportunities

Total Income for FY24 was \$14.8 million, comprising operating revenue of \$3.8 million and other income of \$11.0 million. Net underlying expenditure for FY24 was \$30.3m (allowing for R&D tax incentives, and grant revenue, and excluding ongoing and one-off transaction expenses associated with Imbio). The Company made significant investments in go-to-market initiatives in the U.S. and the integration of the Imbio operations. In addition, we attended multiple global industry conferences during the year which are critical to build awareness and develop commercial opportunities. It is pleasing to see that these opportunities are starting to yield results, with substantive interest from academic hospitals and facilities, and commercial partners alike.

The Company reported a net loss after tax of \$36.0 million for FY24 and had a net cash balance of \$30.6 million at the end of the period, with zero debt.

Our clear focus is commercialisation and during FY2024 4DMedical built foundations key to achieving our strategic ambitions. I want to share 4 highlights.

- Acquisition of Imbio
- Philips reseller agreement
- US reimbursement and U.S. pilots
- Product distribution in ANZ and funding for CT:VQ trials



1. Acquisition of Imbio

In December 2023 we acquired Imbio, a leading medical imaging AI company, bringing new revenue streams and providing 4DMedical with a complete lung analysis product portfolio; in effect “owning the lung”. Imbio’s worldwide channel partnerships have also brought additional entry points for all 4DMedical products.

Andreas will talk through our comprehensive portfolio.

This suite of lung analysis applications is now the basis for the 4DMedical product offering to referrers in Australia and the U.S.. Moreover, the inclusion of new market opportunities across our companion imaging offerings is opening multiple avenues for growth globally, as we partner with medical device and pharmaceutical companies. In addition, our expanded product suite, is generating considerable interest across various payer markets including radiology, respiratory and cardiology specialists, as well as providing a compelling offering to the VA.

2. Philips reseller agreement

4DMedical has signed a distribution agreement to have Philips as an authorised reseller in the U.S.. Philips is a global iconic company in medical imaging and healthcare, with technology used in 50% of U.S. Veterans Affairs clinics. This transformative agreement allows for the expansion of our technologies particularly with the U.S. Department of Veterans Affairs. We recently announced, we are working closely with Philips to operationalise the reseller agreement, with significant progress already made in respect of identification of opportunities, training, and joint marketing activities. We are also very excited about the prospect of our CEO, Andreas Fouras, co-presenting with Philips North America CEO, Jeff DiLullo, at Radiology Society of North America conference in early December and demonstrates the depth of commitment both organisations have in ensuring the reseller agreement is a success.

Our partnership with Philips is especially relevant in the context of the PACT Act, a landmark US\$280 billion initiative to support Veterans exposed to respiratory hazards whilst on deployment. Our XV LVAS® and LDAf technologies are currently the two leading non-invasive technologies capable of assessing deployment-related respiratory diseases, making them ideally suited to meet the VA’s needs.

Beyond the VA, the broader U.S. market presents a substantial opportunity. In 2019, approximately 10.9 million thoracic CT scans were performed across the U.S., representing an addressable market of \$5.7 billion. With the recent CMS reimbursement approval for XV LVAS® and CT LVAS™, paying \$311 and \$650 per scan respectively, we have a powerful platform to engage both Philips and private healthcare providers in expanding our footprint in this segment.

3. U.S. reimbursement

Securing U.S. reimbursement for XV LVAS® and CT LVAS™ marks a defining moment for 4DMedical. With CMS reimbursement, we have the opportunity for broad adoption at more than 4,000 Medicare-certified hospitals and over 65 million Americans enrolled in Medicare.

We have code for XV LVAS®, with a reimbursement rate of \$311 per scan and additionally CT LVAS™ was granted coverage at \$650.50 per scan under Medicare’s 2024 rulings. This development secures access to critical lung diagnostics for Medicare beneficiaries but also sets a benchmark rate that private insurers are likely to follow or exceed. CT LVAS also sets minimum benchmark for CTVQ



4. Product distribution in Australia and Federal Government grant

In Australia, 4DMedical continued to expand the access to CT LVAS™, accelerating the rollout across the I-MED Radiology Network, Integral Diagnostics, Jones Radiology, and Spectrum Medical Imaging.

As 4DMedical continues to innovate and expand, it remains committed to providing life changing respiratory diagnostics and enhancing patient care. The progress made in FY24 sets a solid foundation for future growth and success.

The Company continues to make progress with the XV Scanner and MRFF grant, with two sites, being Prince of Wales Hospital and Vanderbilt University Medical Centre, now collecting human scans for clinical evidence. In addition, the award of \$1.9 million in non-dilutive funding from the Federal Government through the CRC-P grant program will facilitate expansion and acceleration of 4DMedical's CT:VQ clinical trial program in partnership with I-MED and Macquarie University. These trials are specifically designed to provide the evidence necessary to empower physicians to rapidly substitute 4DMedical's CT:VQ for nuclear medicine VQ scans. Andreas will talk further about CT:VQ in his presentation.

These achievements illustrate the achievements made in FY2024. They reflect the dedication of our team, the strength of our partnerships, and the focused execution of our vision.

I would like to extend my gratitude and appreciation to my fellow directors and recognise the contribution of our global staff to the continuing success of 4DMedical. We have much to do, but with the momentum we have garnered in FY24, I look forward to next year with great confidence.

On behalf of the Board of 4DMedical, thank you for your attendance today and I kindly seek your approval of the resolutions placed before you which have the full support of the 4DM board.



The future of lung health

4DMedical Limited (ASX:4DX)
Annual General Meeting
20 November 2024

4DMedical Limited ABN 31 161 684 831



Disclaimer

This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (**Company** or **4DMedical**). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (**Group**) and their activities current as of 20 November 2024 unless otherwise stated and the information remains subject to change without notice. This presentation contains general background information and does not purport to be complete. No attempt has been made to independently verify the information contained in this presentation.

Not an offer or financial product advice

The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly, any securities to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement or recommendation to enter into, any contract whatsoever relating to any securities.

This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian *Corporations Act 2001* (Cth) (**Corporations Act**) or other offer document under Australian law or the law of any other jurisdiction. This presentation does not constitute an invitation to apply for or purchase securities and does not include any application form for securities. This presentation does not constitute an advertisement for an offer or proposed offer of securities. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation.

The distribution of this presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this presentation may not be distributed or released in the United States. The securities in the Company (**Securities**) have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (**U.S. Securities Act**), or the securities laws of any state or other jurisdiction of the United States. Accordingly, the Securities may not be offered or sold, directly or indirectly, in the United States, unless they have been registered under the U.S. Securities Act (which the Company has no obligation to do or procure) or are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable securities laws of any state or other jurisdiction of the United States.

Overview



Agenda

1. Opening & introductions
2. Chair's address
3. CEO's address
4. Procedural matters
5. Formal business
6. Closing remarks

Board of Directors – significant medical and commercial sector experience



LIL BIANCHI

**Non-Executive Chair
Chair, Audit & Risk Committee**

Experienced contributor of business transformations for US listed technology companies with a beneficial technology product expertise in AI and SaaS offerings.



Dr ANDREAS FOURAS PhD

Managing Director and CEO

Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical's core technologies.



Dr ROBERT A. FIGLIN MD

Non-Executive Director

Globally recognised leader in genitourinary and thoracic oncology, as well as Editor of the Kidney Cancer Journal and Spielberg Family Chair in Hematology/Oncology at Cedars Sinai.



Dr GERALDINE MCGINTY MD

Non-Executive Director

Internationally recognised expert in health care strategy and imaging economics, and prominent advocate for patient-centered care. A Professor of Radiology and Population Health Sciences at Weill Cornell Medicine in New York City, she serves as Senior Associate Dean for Clinical Affairs.



JULIAN SUTTON

Non-Executive Director

Chartered Financial Analyst who began his career as an actuarial analyst in Melbourne before moving into funds management with Schroders and Credit Suisse in London.



JOHN LIVINGSTON

Executive Director

Founding partner of ASX listed Integral Diagnostics (ASX:IDT) and an industry leader in the implementation of PACS and RIS in radiological settings.

Key Advisors



Dr DAVID J. SHULKIN MD
Key Advisor

Highly respected physician and health care executive, Dr Shulkin was previously the Secretary of the United States Department of Veterans Affairs (VA). As Secretary of the VA, Dr Shulkin oversaw the US government's second largest agency, with over 350,000 employees and 1,700 facilities, serving over 9 million Veterans.



Dr SAM HUPERT MBBS
Advisory Board Member

Co-founder and Chief Executive Officer of Pro Medicus Ltd (ASX:PME) which develops and markets health imaging software primarily for radiologists in the U.S., Europe and Australia.



Prof BRUCE THOMPSON PhD
Advisory Board Member

Board Member and Past President of the Thoracic Society of Australia and New Zealand; currently Dean of the School of Health Sciences at the University of Melbourne, and a former Head of Physiology Services at the Alfred Hospital.

Chair's address



LIL BIANCHI Non-Executive Chair

Experienced contributor of business transformations for US listed technology companies with a beneficial technology product expertise in AI and SaaS offerings.



FY24 Financial Summary

- 4DMedical reported a net cash balance of \$30.6 million at 30 June 2024, with zero debt.
- Total operating revenue of \$3.8 million, up 422% on pcp, with total income of \$14.8 million including \$11.0 in other income.
- Total net operating expenditure \$30.3 million, up 2.5%, reflecting a reduction in R&D and clinical trial expenditure offset by increased investment in commercialisation activities.

\$30.6m

Cash reserves
(zero debt)

\$3.8m

Operating Revenue
+422% vs FY23

\$30.3m

Net operating
expenditure

\$14.8m

Total Income
(includes \$11.0m of
grant income and R&D
tax credits)

(3.4%)

Reduction in underlying
4DMedical operating
expenses

145

Employees globally

CEO's address



Dr ANDREAS FOURAS PhD
Managing Director


Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical's core technologies.



Global respiratory diagnostic market valued at US\$31.4 billion per annum

Four existing lung diagnostic technologies account for 99% of all lung scans:

Expenditure (USD \$B)



Country	Spend (\$USD)	Procedures
U.S.A	13,716M	73.5M
Others	4,964M	59.8M
Germany	2,678M	20.3M
Japan	1,905M	22.8M
China	1,851M	101.6M
UK	1,351M	8.9M
France	1,191M	10.2M
Spain	780M	8.4M
Italy	681M	8.5M
Canada	606M	8.0M
South Korea	450M	6.8M
Turkey	346M	16.1M
Australia	285M	5.3M
India	276M	25.3M
Switzerland	197M	1.2M
Israel	69M	1.1M

378 million global respiratory diagnostics tests performed annually¹

1. Figures adapted from Frost and Sullivan Report 2020 USD \$31.3 billion global spend annually (table) 9

Current lung diagnostics are failing us

Lung health screening (COPD, silicosis, black lung, lung cancer)



- COPD – 4th largest cause of mortality in world¹
- Silicosis – 600,000 Australian workers exposed to silica dust per annum

Unexplained dyspnoea (shortness of breath)



- \$12.2bn cost of breathlessness in Australia²
- 9.5% of Australians have clinically relevant breathlessness

Burn Pits & DRRD (Deployment-related Respiratory Disease)




- >6million service personnel exposed to airborne toxic hazards³
- No standard diagnostics detecting presence or absence of DRRD

¹ thelancet.com/lancetgh. Volume 11, August 2023

² The health and economic burden of breathlessness, Australia, 2019: a national survey

³ publichealth.va.gov/exposures/burnpits/index.asp


Comprehensive chest diagnostics product suite



*FDA cleared, ** CE Approved, ***FDA clearance in progress, ^pending submission


A complete lung health solution

Pulmonary Structure




Lung Density*

Emphysema, HAA, Fissures



Lung Texture**

ILD's / Fibrosis



IQ-UIP***

IPF Screening



Airway Analysis^

Airway morphology




Lung Nodules*

Lung Cancer
(partner solution)




Pulmonary Function




XV LVAS®*

Dynamic Ventilation
Analysis (Fluoro)




CT LVAS™

CT-based Ventilation
Analysis



CT VQ***

Next Gen VQ
(Ventilation + Perfusion)




Functional LDA*

Air Trapping + Emphysema




Cardiovascular




CAC*

Coronary Calcification/Heart
Disease



PH Assessment*

Hypertension (RV/LV, MPA,
Pa/Ao)



Volumetric Diameter Mapping^

Aortic Aneurysm Analysis



Pulmonary Vessel

FUTURE: Vascular morphology



Total Solution

Combined product suite

Enabling access to key imaging
modalities: CT, X-ray

Market access

in USA, EU, and AU

Established networks

With market distributors

US reimbursement

for XVLVAS®, CT LVAS™ & LDAf
(Medicare)

Expanded product pipeline

CTVQ + IQ-UIP

Solving the clinical conundrum for doctors across multiple care areas

Clinical Conundrum in Lung Assessment

A mismatch between clinical tests and imaging often occurs, whereby anatomic findings can overlap, lag, or precede clinical symptoms.

Need structural and functional data/information to make a better, informed clinical decision.

Not solved by historical standard of care testing (Spirometry, X-ray, CT scans)

Clinical Tools Needed to Solve the Conundrum

Functional lung analysis providing visual qualitative and quantitative assessment of **ventilation**



Structural lung analysis providing visual qualitative and quantitative assessment of lung **anatomy**



Applications for Technologies in Clinical Practice

Unexplained dyspnoea

Example technology

A complex clinical presentation

Is it Lung related?
Is it Cardiac related?
Is it other causes or psychosomatic?

CT LVAS™
CAC
PAH

Restrictive diseases

DRRD / CB Deployment-related respiratory disease/
Constrictive bronchiolitis | *ILD* Interstitial Lung Disease |
IPF Idiopathic pulmonary fibrosis | *Dust Exposures* —
Silicosis, asbestosis, pneumoconiosis

XV LVAS®
LDA
LTA
IQ-UIP

Obstructive diseases

COPD Chronic Obstructive Pulmonary Disease—
Emphysema, Chronic Bronchitis | *Asthma* | *CF* Cystic
Fibrosis


LDA
CT LVAS™
XV LVAS®

Intervention and pharmaceutical

Lung Reduction therapies | Disease progression /
regression | Compliance

LDA
IQ-UIP
CT: VQ
XV LVAS®
LTA

FY24 achievements – building the foundations



Commercialisation strategy

	US Government	US Commercial	Global Partnerships	Australia
Enablers	Philips		Olympus	I-MED
	Exclusive	Non-exclusive	Genentech	Jones Radiology
	Reimbursement		Nuance/Aidoc/Blackford	Integral Diagnostics
Sector	Veterans Affairs	Community-based Clinics	Global Pharma Companies	Community Clinics
	Department of Defense	Academic institutes	Global Device Companies	Radiology Networks
	Federal & State facilities	Health Systems (IDN's)		Public Hospitals
		Radiology Networks		National Programs
Rationale	Unmet need to solve for respiratory issues, including deployment-related respiratory diseases (DRRD)	Largest lung diagnostic market with huge economic scale	Large burden of data needed where our technologies can accelerate progress	Early adoption of core technologies in key players to build influence and scale
	PACT Act - US\$280 billion commitment over ten years, covers numerous respiratory illnesses as presumptive conditions. Healthcare eligibility to 3.5 million post-9/11 veterans. Bi-partisan support of veteran care. Philips has long established and significant existing partnerships	Reimbursement rates established covering 4,000 facilities. Over 14,5k CT scanners deployed. Shortage of clinicians creates opportunity for AI tools and faster clinical insights	Custom imaging biomarker development and patient selection tools shorten clinical trial time and expense in the multi billion-dollar pharma development sector. AI marketplaces increase access and coverage through deployment capabilities	Australian radiology is innovative and readily accessible through community practices, networks and hospitals, with a high proportion of CT Scanners (33.9%) . Chest CT procedures through Medicare = 330k per annum. Proximity and collaboration with our development team speeds innovation.

Philips overview

Philips Healthcare – portfolio of businesses²

€18.2bn in sales (2023), ~70% in #1 or #2 positions; ~40% sales recurring revenue; ~70k employees
42% North America, 21% Western Europe, 9% other mature geographies, 28% growth geographies

Diagnosis & treatment:

~50% of sales (2023 full year)

Diagnostic imaging

Top 3 player

Ultrasound

#1 Cardiac

Image Guided Therapy

#1 Systems & devices

Systems, smart devices, software and services, powered by AI-enabled informatics

Supporting precision diagnosis and minimally invasive treatment in a growing number of therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology

Connected care:

~30% of sales (2023 full year)

Enterprise Informatics

#1 Imaging PACS & interoperability

Monitoring

#1 in Hospital
#1 in Ambulatory

Sleep & Respiratory Care

#2 Globally

Ambulatory, home-based and in-hospital monitoring and workflow solutions fueled by advanced interoperability and patient data insights

Connecting patients and caregivers across care settings, delivering clinical, operational and therapeutic solutions

Personal health:

~20% of sales (2023 full year)

Personal Health

#2 Oral Healthcare
#1 Male Grooming
#2 Infant Feeding

Broad range of consumer solutions to support people in proactively managing their health and wellbeing


Market-leading capabilities integrating platforms, informatics, and services

1. Source: Philips website: <https://www.philips.com/a-w/about>
2. Source: Philips Investor Centre: <https://www.philips.com/a-w/about/investor-relations.html>



Key business units for 4DMedical

Philips reseller agreement



1. U.S. Department of Veterans Affairs
2. Figures adapted from Frost and Sullivan Report 2020 USD \$31.3 billion global spend annually (table)

Procedural matters

Formal business

Items of business

- Item 1:** Financial Report, Directors' Report and Auditors Report
- Item 2:** Remuneration Report
- Item 3:** Re-election of Director, Dr Robert A. Figlin
- Item 4:** Issue of securities to Directors
- Item 5:** Issue of securities to Directors in lieu of base directors' fees – Ms Lil Bianchi and Dr Geraldine McGinty
- Item 6:** Grant of Options to the Managing Director and CEO
- Item 7:** Approval of 10% placement capacity
- Item 8:** Ratification of prior issue of shares

Formal business

Item 1: Financial Report, Directors' Report and Auditors Report

To receive and consider the Financial Report of the Company and its controlled entities and the Reports of the Directors and Auditor for the year ended 30 June 2024.

Formal business

Item 2: Remuneration Report

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That the Remuneration Report, as contained in the Directors’ Report for the year ended 30 June 2024, is adopted.”

In Favour	Against	Proxy Discretion	Abstain
15,628,689	8,141,784	3,024,919	981,043
58.33%	30.38%	11.29%	

Further Information:

- The Board unanimously recommends that Shareholders vote in favour of Item 2.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Formal business

Item 3: Re-election of Director, Dr Robert A. Figlin

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, for the purposes of clause 13.3(b) of the Constitution, ASX Listing Rule 14.4, and for all other purposes, Dr Robert A. Figlin, a non-executive director appointed on 9 December 2016 retires in accordance with clause 13.3(a) of the Constitution, and being eligible, is re-elected as a director.”

In Favour	Against	Proxy Discretion	Abstain
89,116,834	289,674	3,157,374	128,082
96.28%	0.31%	3.41%	

Further Information:

- The Board (other than Dr Figlin) unanimously recommends that Shareholders vote in favour of Item 3.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.

Formal business

Items 4A to 4E: Approval for the proposed issue of securities to Directors

Item 4A

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 91,257 Options to **Ms Lil Bianchi** (or her nominee) under the Incentive Plan on the terms and conditions described in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
18,114,801	6,287,208	3,013,691	360,715
66.07%	22.93%	10.99%	

Item 4B

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 60,147 Options to **Mr John Livingston** (or his nominee) under the Incentive Plan on the terms and conditions described in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
15,614,292	8,798,464	3,008,691	354,968
56.94%	32.09%	10.97%	

Item 4C

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 60,147 Options to **Mr Julian Sutton** (or his nominee) under the Incentive Plan on the terms and conditions described in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
15,541,685	8,855,324	3,018,691	360,715
56.69%	32.30%	11.01%	

Formal business

Items 4A to 4E: Approval for the proposed issue of securities to Directors

Item 4D

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 60,147 Restricted Stock Units to **Dr Robert A. Figlin** (or his nominee) under the Incentive Plan on the terms and conditions described in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
18,091,940	6,295,629	3,018,691	370,155
66.01%	22.97%	11.01%	

Item 4E

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 60,147 Restricted Stock Units to **Dr Geraldine McGinty** (or her nominee) under the Incentive Plan on the terms and conditions described in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
20,467,840	3,879,729	3,018,691	410,155
74.79%	14.18%	11.03%	

Further Information:

- The Chair of the meeting intends to vote undirected proxies in favour of Items 4A to 4E.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Formal business

Items 5A and 5B: Approval for the proposed issue of securities to Directors in lieu of base directors' fees

Item 5A

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

"That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 105,649 Options to **Ms Lil Bianchi** (or her nominee) in lieu of base directors' fees under the Incentive Plan on the terms and conditions described in the Explanatory Statement."

In Favour	Against	Proxy Discretion	Abstain
22,101,568	2,225,824	3,104,109	344,914
80.57%	8.11%	11.32%	

Item 5B

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

"That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 77,640 Restricted Stock Units to **Dr Geraldine McGinty** (or her nominee) in lieu of base directors' fees under the Incentive Plan on the terms and conditions described in the Explanatory Statement."

In Favour	Against	Proxy Discretion	Abstain
22,123,936	2,178,737	3,033,410	440,332
80.93%	7.97%	11.10%	

Further Information:

- The Board (other than Ms Bianchi and Dr McGinty) unanimously recommends that Shareholders vote in favour of Items 5A and 5B.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Formal business

Item 6: Grant of Options to the Managing Director and CEO

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, for the purposes of ASX Listing Rule 10.14, sections 200B and 200E of the Corporations Act and for all other purposes, Shareholders approve the proposed grant of up to 775,339 Options, and potential termination benefits, to Managing Director and CEO, Dr Andreas Fouras, under the Incentive Plan and on the terms described in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
16,940,616	7,495,055	3,023,663	317,081
61.69%	27.30%	11.01%	

Further Information:

- The Board (other than Dr Fouras) unanimously recommends that Shareholders vote in favour of Item 6.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Formal business

Item 7: Approval of 10% Placement Facility

To consider, and if thought fit, to pass, the following as a **special** resolution:

“That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the issue of Equity Securities up to 10% of the fully paid ordinary issued capital of the Company (at the time of issued) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
79,963,161	9,288,824	3,137,548	302,431
86.55%	10.05%	3.40%	

Further Information:

- The Board unanimously recommends that Shareholders vote in favour of Item 7.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Formal business

Item 8: Ratification of prior issue of Shares

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 19,000,000 Shares to Alpha Investment Partners Pty Ltd on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
88,527,154	643,831	3,147,548	373,431
95.89%	0.70%	3.41%	

Further Information:

- The Board unanimously recommends that Shareholders vote in favour of Item 8.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Poll



4D Medical Limited (ASX:4DX)
Annual General Meeting
20 November 2024

Copyright © 4D Medical Limited 2024
Level 7, Melbourne Connect
700 Swanston Street
Melbourne, Victoria 3053
Australia

www.4dmedical.com

ABN 31 161 684 831

